Free Newsletter
Endo plunks down $637M for Indevus
Free newsletter via e-mail
Tools
Endo Pharmaceuticals says it will be acquiring Indevus Pharmaceuticals for $370 million in cash and an additional $267 in future payouts, in an effort to move away from the pain-management business and into more-lucrative therapeutic areas with a less competition. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: